贝伐珠单抗联合化疗治疗结直肠癌寡转移术后患者的疗效及对中位无进展生存期的影响

doi:10.3969/j.issn.1006-5725.2026.05.004

Abstract

Abstract:

Objective To explore the efficacy of bevacizumab in combination with FOLFOX standard chemotherapy for the treatment of postoperative patients with oligometastatic colorectal cancer and its impact on the median progression-free survival （mPFS）. Methods The clinical data of postoperative patients with oligometastatic colorectal cancer admitted to Fuyang People's Hospital from January 2021 to June 2024 were retrospectively collected. Based on the treatment regimens received after surgery， the patients were divided into the combination group （bevacizumab + FOLFOX standard chemotherapy， n = 30） and the chemotherapy group （FOLFOX standard chemotherapy， n = 72）. All patients completed 6 cycles of treatment （with 21 days as 1 cycle）. The therapeutic effects， serum marker levels before and after treatment ［carcinoembryonic antigen （CEA）， carbohydrate antigen 199 （CA199）， platelet count/lymphocyte count ratio （PLR）， lymphocyte count/monocyte count ratio （LMR）， C-reactive protein/albumin ratio （CRP/ALB）］， and toxic and side effects of the two groups were systematically counted， analyzed， and compared. The follow-up survival outcomes were compared （with follow-up conducted once every 3 months until November 1， 2025）. Additionally， the correlation between serum markers and the survival prognosis of patients was analyzed， and Cox regression analysis was employed to screen the prognostic factors of patients. Results The overall efficacy grade of the combined group was superior to that of the chemotherapy group， and the disease control rate （DCR） was higher （P < 0.05）. After treatment， the levels of serum CEA， CA199， PLR， and CRP/ALB in the combined group were lower than those before treatment within the same group and those after treatment in the chemotherapy group （P < 0.05）， whereas the LMR was higher （P < 0.05）. There was no statistically significant difference in the incidence of toxic and side effects between the two groups （P > 0.05）. At the end of the follow-up， the combined group exhibited longer average progression-free survival （PFS）， median PFS （mPFS）， average overall survival （OS）， and median OS （P < 0.05）. A total of 102 patients were classified into the progression group （progression or tumor-related death， n = 62） and the non-progression group （surviving during follow-up， n = 40） based on survival prognosis. At the end of treatment， the levels of serum CEA， CA199， PLR， and CRP/ALB in the progression group were higher than those in the non-progression group， while the LMR was lower （P < 0.05）. At the end of treatment for patients with oligometastatic colorectal cancer， serum CEA， CA199， PLR， and CRP/ALB were negatively correlated with mPFS and median OS， whereas LMR was positively correlated with mPFS and median OS （P < 0.05）. Cox regression analysis indicated that high CEA and high CRP/ALB were independent risk factors for the prognosis of patients with oligometastatic colorectal cancer （P < 0.05）， while bevacizumab + FOLFOX chemotherapy and high LMR level were protective factors （P < 0.05）. Conclusions Bevacizumab combined with FOLFOX standard chemotherapy can enhance the disease control rate among postoperative patients with oligometastatic colorectal cancer， decrease the expression level of tumor-related factors， and offer a better survival prognosis with controllable adverse reactions when compared with chemotherapy alone.

Key words: colorectal cancer, oligometastatic, FOLFOX chemotherapy, bevacizumab, survival prognosis

CLC Number:

R979.1

Bin YU,Jian ZHOU,Tian TIAN,Fusheng WANG. The efficacy of bevacizumab combined with chemotherapy in the treatment of postoperative patients with oligometastatic colorectal cancer and its impact on mpfs median progression-free survival[J]. The Journal of Practical Medicine, 2026, 42(5): 750-758.

Figures/Tables 10

Tab.1

Tab.2

Tab.3

Tab.4

Tab.5

Fig.1

Tab.6

Tab.7

Fig.2

Tab.8

References 35

[1]	XIA C， DONG X， LI H， et al. Cancer statistics in China and United States， 2022： Profiles， trends， and determinants［J］. Chin Med J （Engl）， 2022， 135（5）： 584-590. doi： 10.1097/CM9.0000000000002108 . doi: 10.1097/CM9.0000000000002108
[2]	SHAUKAT A， KAHI C J， BURKE C A， et al. ACG Clinical Guidelines： Colorectal Cancer Screening 2021［J］. Am J Gastroenterol， 2021， 116（3）： 458-479. doi： 10.14309/ajg. 0000000000001122 . doi: 10.14309/ajg. 0000000000001122
[3]	WU M， WU X， WANG X， et al. IDO1/COX2 Expression Is Associated with Poor Prognosis in Colorectal Cancer Liver Oligometastases［J］. J Pers Med， 2023， 13（3）： 496. doi： 10.3390/jpm13030496 . doi: 10.3390/jpm13030496
[4]	LI B， WEI Z， WANG Z， et al. Fusobacterium nucleatum induces oxaliplatin resistance by inhibiting ferroptosis through E-cadherin/β-catenin/GPX4 axis in colorectal cancer［J］. Free Radic Biol Med， 2024， 220： 125-138. doi： 10.1016/j.freeradbiomed. 2024. 04.226 . doi: 10.1016/j.freeradbiomed. 2024. 04.226
[5]	JUŘICA J， ŠUVEROVÁ P， GONĚC R， et al. High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy［J］. Ceska Slov Farm， 2023， 72（3）： 107-112. doi:10.5817/csf2023-3-107 doi: 10.5817/csf2023-3-107
[6]	LENZ H J， PARIKH A， SPIGEL D R， et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer： Phase 2 results from the CheckMate 9X8 randomized clinical trial［J］. J Immunother Cancer， 2024， 12（3）： e008409. doi： 10.1136/jitc-2023-008409 . doi: 10.1136/jitc-2023-008409
[7]	ROSSINI D， ANTONIOTTI C， LONARDI S， et al. Upfront Modified Fluorouracil， Leucovorin， Oxaliplatin， and Irinotecan Plus Panitumumab Versus Fluorouracil， Leucovorin， and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer： The Phase Ⅲ TRIPLETE Study by GONO［J］. J Clin Oncol， 2022， 40（25）： 2878-2888. doi： 10.1200/JCO.22.00839 . doi: 10.1200/JCO.22.00839
[8]	WANG F， JIN Y， WANG M， et al. Combined anti-PD-1， HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer： A randomized phase 2 trial［J］. Nat Med， 2024， 30（4）： 1035-1043. doi： 10.1038/s41591-024-02813-1 . doi: 10.1038/s41591-024-02813-1
[9]	AHN D H， BARZI A， RIDINGER M， et al. Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer： A Phase Ib Clinical Study［J］. Clin Cancer Res， 2024， 30（10）： 2039-2047. doi： 10.1158/1078-0432 . doi: 10.1158/1078-0432
[10]	中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范（2020版）［J］. 中华消化外科杂志， 2020， 19（6）： 563-588. doi： 10.3760/cma.j.cn115610-20200504-00348 . doi: 10.3760/cma.j.cn115610-20200504-00348
[11]	ARAS M， ERDIL T Y， DANE F， et al. Comparison of WHO， RECIST 1.1， EORTC， and PERCIST criteria in the evaluation of treatment response in malignant solid tumors［J］. Nucl Med Commun， 2016， 37（1）： 9-15. doi： 10.1097/MNM. 0000000000000401 . doi: 10.1097/MNM. 0000000000000401
[12]	FREITES-MARTINEZ A， SANTANA N， ARIAS-SANTIAGO S， et al. Using the Common Terminology Criteria for Adverse Events （CTCAE-Version 5.0） to Evaluate the Severity of Adverse Events of Anticancer Therapies［J］. Actas Dermosifiliogr （Engl Ed）， 2021， 112（1）： 90-92. doi： 10.1016/j.ad.2019.05.009 . doi: 10.1016/j.ad.2019.05.009
[13]	NESS R M， LLOR X， ABBASS M A， et al. NCCN Guidelines^® Insights： Colorectal Cancer Screening， Version 1.2024［J］. J Natl Compr Canc Netw， 2024， 22（7）： 438-446. doi： 10.6004/jnccn. 2024.0047 . doi: 10.6004/jnccn. 2024.0047
[14]	SUYDAM C R， SCHLUSSEL A T. Management of Oligometastatic Colorectal Cancer［J］. Surg Clin North Am， 2024， 104（3）： 619-629. doi： 10.1016/j.suc.2023.11.011 . doi: 10.1016/j.suc.2023.11.011
[15]	CARCONI C， CERRETI M， ROBERTO M， et al. The management of oligometastatic disease in colorectal cancer： Present strategies and future perspectives［J］. Crit Rev Oncol Hematol， 2023， 186： 103990. doi： 10.1016/j.critrevonc.2023.103990 . doi: 10.1016/j.critrevonc.2023.103990
[16]	郑凯，张天可，付文政. XPC基因遗传变异对接受奥沙利铂辅助化疗方案的Ⅲ期结直肠癌患者的神经毒性及预后的影响［J］. 实用医学杂志， 2021， 37（10）： 1301-1306. doi：10.3969/j.issn. 1006-5725.2021.10.014 . doi: 10.3969/j.issn. 1006-5725.2021.10.014
[17]	WANG H， ZHENG J， PAN J， et al. Neoadjuvant triple-modality therapy with immune checkpoint blockade， anti-angiogenesis， and chemotherapy enhances pathologic response and survival in locally advanced and metastatic colorectal cancer： A multicenter cohort study［J］. Int J Colorectal Dis， 2025， 40（1）： 154. doi： 10.1007/s00384-025-04945-3 . doi: 10.1007/s00384-025-04945-3
[18]	MILLER E D， HITCHCOCK K E， ROMESSER P B. Oligometastatic Colorectal Cancer： A Review of Definitions and Patient Selection for Local Therapies［J］. J Gastrointest Cancer， 2023， 54（4）： 1116-1127. doi： 10.1007/s12029-022-00900-5 . doi: 10.1007/s12029-022-00900-5
[19]	YANG L， XIE H J， LI Y Y， et al. Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer （Review）［J］. Oncol Rep， 2022， 47（4）： 82. doi： 10.3892/or. 2022. 8293 . doi: 10.3892/or. 2022. 8293
[20]	DE BAERE T， TSELIKAS L， DELPLA A， et al. Thermal ablation in the management of oligometastatic colorectal cancer［J］. Int J Hyperthermia， 2022， 39（1）： 627-632. doi： 10.1080/02656736.2021.1941311 . doi: 10.1080/02656736.2021.1941311
[21]	CHEN Y W， MCKAY R R. Mitigating the Risk of Skeletal Events in Metastatic Renal Cell Carcinoma［J］. Eur Urol Focus， 2025， 11（3）： 425-428. doi： 10.1016/j.euf.2025.04.007 . doi: 10.1016/j.euf.2025.04.007
[22]	ZHENG Y， ZHOU R， CAI J， et al. Matrix Stiffness Triggers Lipid Metabolic Cross-talk between Tumor and Stromal Cells to Mediate Bevacizumab Resistance in Colorectal Cancer Liver Metastases［J］. Cancer Res， 2023， 83（21）： 3577-3592. doi： 10.1158/0008-5472 . doi: 10.1158/0008-5472
[23]	WANG J， LIU C， WANG P， et al. Bioengineered Tumor-Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance［J］. Adv Sci （Weinh）， 2025， 12（23）： e2417714. doi： 10.1002/advs.202417714 . doi: 10.1002/advs.202417714
[24]	TAKAKURA Y， SHINOZAKI K， IKEDA S， et al. Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases： A Randomized Phase II Trial （HiSCO-01）［J］. Ann Gastroenterol Surg， 2025， 9（6）： 1253-1262. doi： 10.1002/ags3.70035 . doi: 10.1002/ags3.70035
[25]	BOND M J G， BOLHUIS K， LOOSVELD O J L， et al. First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases： Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial［J］. JAMA Oncol， 2025， 11（1）： 36-45. doi： 10.1001/jamaoncol.2024.5174 . doi: 10.1001/jamaoncol.2024.5174
[26]	LIU X， CHEN Z， YAN P， et al. Treatment mechanism and research progress of bevacizumab for glioblastoma［J］. Am J Cancer Res， 2025， 15（4）： 1874-1901. doi： 10.62347/RNUE7193 . doi: 10.62347/RNUE7193
[27]	OHISHI T， KANEKO M K， YOSHIDA Y， et al. Current Targeted Therapy for Metastatic Colorectal Cancer［J］. Int J Mol Sci， 2023， 24（2）： 1702. doi： 10.3390/ijms24021702 . doi: 10.3390/ijms24021702
[28]	ELSAYED A， PLÜSS L， NIDEROEST L， et al. Optimizing the Design and Geometry of T Cell-Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer［J］. Mol Cancer Ther， 2024， 23（7）： 1010-1020. doi： 10.1158/1535-7163 . doi: 10.1158/1535-7163
[29]	WANG K， MA L， CHEN L， et al. The clinical value of a nomogram constructed from CEA， CA199， PT， FIB， tumor differentiation and TNM stage in colorectal cancer［J］. Cancer Biomark， 2023， 38（4）： 537-549. doi： 10.3233/CBM-230116 . doi: 10.3233/CBM-230116
[30]	张昊晨，周欣毅，富栋梁，等. rigosertib联合化疗对Kirsten大鼠肉瘤病毒癌基因同源物突变型结直肠癌小鼠的疗效和不良反应［J］. 中华肿瘤杂志， 2023， 45（2）： 138-145. doi： 10.3760/cma.j.cn112152-20210514-00379 . doi: 10.3760/cma.j.cn112152-20210514-00379
[31]	MISIEWICZ A， DYMICKA-PIEKARSKA V. Fashionable， but What is Their Real Clinical Usefulness？ NLR， LMR， and PLR as a Promising Indicator in Colorectal Cancer Prognosis： A Systematic Review［J］. J Inflamm Res， 2023， 16： 69-81. doi： 10.2147/JIR.S391932 . doi: 10.2147/JIR.S391932
[32]	GAWIŃSKI C， MICHALSKI W， MRÓZ A， et al. Correlation between Lymphocyte-to-Monocyte Ratio （LMR）， Neutrophil-to-Lymphocyte Ratio （NLR）， Platelet-to-Lymphocyte Ratio （PLR） and Tumor-Infiltrating Lymphocytes （TILs） in Left-Sided Colorectal Cancer Patients［J］. Biology （Basel）， 2022， 11（3）： 385. doi： 10.3390/biology11030385 . doi: 10.3390/biology11030385
[33]	FENG J， WANG L， WANG L， et al. Clinical significance of Osaka prognostic score based on nutritional and inflammatory status in patients with esophageal squamous cell carcinoma［J］. BMC Cancer， 2022， 22（1）： 284. doi： 10.1186/s12885-022-09406-6 . doi: 10.1186/s12885-022-09406-6
[34]	张旭，张庆，郭帅，等. 联合贝伐珠单抗的新辅助治疗对局部晚期直肠癌的疗效与安全性分析［J］. 中国普通外科杂志， 2024， 33（10）： 1623-1632. doi： 10.7659/j.issn.1005-6947. 2024.10.009 . doi: 10.7659/j.issn.1005-6947. 2024.10.009
[35]	王翠翠，乔万通，姚俊英，等. 营养控制状态评分联合预后营养指数评估老年结直肠癌患者合并贫血风险的临床应用价值［J］. 实用医学杂志， 2025， 41（17）： 2696-2704. doi： 10.3969/j.issn.1006-5725.2025.17.013 . doi: 10.3969/j.issn.1006-5725.2025.17.013

项目	联合组（n = 30）	化疗组（n = 72）	χ²/t值	P值
性别/［例（%）］			0.031	0.860
男	22（73.33）	54（75.00）
女	8（26.67）	18（25.00）
年龄/岁	58.61 ± 5.96	58.86 ± 6.34	0.185	0.854
体质量/kg	62.57 ± 15.71	61.98 ± 18.26	0.155	0.877
ECOG评分/［例（%）］			0.006	0.997
0分	9（30.00）	22（30.56）
1分	15（50.00）	36（50.00）
≥ 2分	6（20.00）	14（19.44）
转移灶数目/个	2.01 ± 0.51	1.98 ± 0.47	0.286	0.775
转移灶最大径/mm	37.11 ± 5.26	36.97 ± 6.17	0.109	0.914
转移灶部位/［例（%）］			0.180	0.981
肺	14（46.67）	32（44.44）
肝	9（30.00）	21（29.17）
骨/脊椎	4（13.33）	12（16.67）
其他	3（10.00）	7（9.72）

项目	联合组（n = 30）	化疗组（n = 72）	χ²/Z值	P值
CR	0（0.00）	0（0.00）	2.112	0.034
PR	18（60.00）	29（40.28）
SD	7（23.33）	16（22.22）
PD	5（16.67）	27（37.50）
ORR	18（60.00）	29（40.28）	3.315	0.068
DCR	25（83.33）	45（62.50）	4.269	0.039

组别	例数	CEA/（ng/mL）		CA199/（U/mL）		PLR
组别	例数	治疗前	治疗结束	治疗前	治疗结束	治疗前	治疗结束
联合组	30	38.96 ± 10.25	12.63 ± 4.02^*	99.56 ± 20.14	30.25 ± 10.01^*	244.36 ± 50.79	170.26 ± 38.39^*
化疗组	72	37.75 ± 9.78	19.52 ± 6.24^*	101.75 ± 23.69	42.26 ± 9.87^*	250.74 ± 48.93	218.14 ± 26.17^*
t值		0.561	5.576	0.444	5.576	0.593	7.289
P值		0.576	< 0.001	0.658	< 0.001	0.554	< 0.001

毒副反应	联合组（n = 30）	化疗组（n = 72）	χ²值	P值
恶心呕吐
1—2级	14（46.67）	32（44.44）	0.042	0.837
3—4级	1（3.33）	3（4.17）	0.131	0.717
腹泻
1—2级	11（36.67）	25（34.72）	0.035	0.851
3—4级	1（3.33）	2（2.78）	0.242	0.623
食欲不振
1—2级	10（33.33）	23（31.94）	0.019	0.891
3—4级	0（0.00）	1（1.39）	0.206	0.650
骨髓抑制
1—2级	15（50.00）	38（52.78）	0.066	0.798
3—4级	2（6.67）	4（5.56）	0.060	0.807
神经毒性
1—2级	12（40.00）	28（38.89）	0.011	0.917
3—4级	2（6.67）	5（6.94）	0.144	0.705
高血压
1—2级	5（16.67）	7（9.72）	0.984	0.321
3—4级	1（3.33）	0（0.00）	0.206	0.650
蛋白尿
1—2级	4（13.33）	2（2.78）	2.568	0.109
3—4级	0（0.00）	0（0.00）	-	-

组别	PFS				OS
组别	均值	95%CI	中位数	95%CI	均值	95%CI	中位数	95%CI
联合组（n = 30）	24.14	20.87 ~ 27.42	27.80	23.69 ~ 31.91	28.72	26.45 ~ 30.99	32.10	28.78 ~ 35.42
化疗组（n = 72）	16.05	13.38 ~ 18.71	8.300	6.84 ~ 9.76	21.50	19.49 ~ 23.51	23.70	21.58 ~ 25.82
Log-rank χ²值	10.020					15.444
P值	0.002					< 0.001

The efficacy of bevacizumab combined with chemotherapy in the treatment of postoperative patients with oligometastatic colorectal cancer and its impact on mpfs median progression-free survival

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 10

References 35

Related Articles 15

Recommended Articles

Metrics

Comments

血清标志物	进展组（n = 62）	无进展组（n = 40）	t值	P值
CEA/（ng/mL）	20.06 ± 6.25	13.52 ± 4.56	5.706	< 0.001
CA199/（U/mL）	42.15 ± 9.25	33.42 ± 10.94	4.329	< 0.001
PLR	217.52 ± 37.69	183.19 ± 17.48	5.392	< 0.001
LMR	3.11 ± 1.07	3.70 ± 1.04	2.749	0.007
CRP/ALB	0.69 ± 0.20	0.55 ± 0.19	3.519	0.001

血清标志物	mPFS		中位OS
血清标志物	r	P值	r	P值
CEA	-0.439	< 0.001	-0.437	< 0.001
CA199	-0.579	< 0.001	-0.559	< 0.001
PLR	-0.628	< 0.001	-0.637	< 0.001
LMR	0.608	< 0.001	0.630	< 0.001
CRP/ALB	-0.587	< 0.001	-0.565	< 0.001

变量	赋值	单因素			多因素
变量	赋值	HR	95%CI	P值	HR	95%CI	P值
治疗方案	FOLFOX化疗= 1，贝伐珠单抗+ FOLFOX化疗= 0	2.568	1.387 ~ 4.752	0.003	0.389	0.208 ~ 0.728	0.003
治疗结束CEA	连续变量（实测值）	1.987	1.301 ~ 3.025	0.001	1.789	1.156 ~ 2.765	0.009
治疗结束CA199	连续变量（实测值）	1.892	1.215 ~ 2.956	0.005	1.456	0.932 ~ 2.278	0.098
治疗结束PLR	连续变量（实测值）	1.678	1.162 ~ 2.421	0.006	1.321	0.923 ~ 1.895	0.125
治疗结束LMR	连续变量（实测值）	0.498	0.301 ~ 0.825	0.007	0.589	0.356 ~ 0.978	0.041
治疗结束CRP/ALB	连续变量（实测值）	1.795	1.187 ~ 2.712	0.006	1.423	1.121 ~ 2.198	0.038

[1]	Yongping ZHENG,Cheng PENG,Ximei REN,Maofeng GONG,Yang LIU. Evaluation of the application value of intraoperative spraying dimethicone as needed combined with oral sulphate solution in colonoscopy [J]. The Journal of Practical Medicine, 2026, 42(4): 611-617.
[2]	Yu XIA,Min DONG,Jinkui WU,Mengbin LI. Research progress on the regulatory mechanism of MYH9 in intestinal epithelial cells and related diseases [J]. The Journal of Practical Medicine, 2026, 42(4): 706-713.
[3]	Huiping ZHU,Jian JIANG,Chunfeng WU,Chen NI,Yang SUN,Yu SONG. The efficacy of sintilimab combined with concurrent chemoradiotherapy in the treatment of oligometastatic non-small cell lung cancer and its influence on the levels of serum VEGF， NF-κB and PD-L1 in patients [J]. The Journal of Practical Medicine, 2026, 42(2): 185-193.
[4]	Na WU,Zetian ZHANG,Rui WANG. The expression and clinical significance of B7⁃H3， PRDX1， and TRX in the serum and tissues of patients with ulcerative colitis and its related colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(9): 1407-1412.
[5]	Likun WANG,Qi HAO,Weihan JIN,Shizheng DONG,Xueliang WU,Xiaofeng HU,Liang WU,Jing XUN,Hongqing MA. Application of multi⁃omics and artificial intelligence in the prediction and diagnosis of liver metastases in colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(7): 1070-1078.
[6]	Linsha KONG,Gaigai HE,Ting LI,Kun FANG,Wei HE,Li WEI. Experimental study of doxorubicin coated by magnetic drug⁃carrying gel beads in the treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(7): 953-959.
[7]	Wei WANG,Min WANG,Minmin CHENG,Tingting. ZHANG. Impacts of safflower polysaccharide on tumor growth and PI3K/Akt/mTOR signal pathway in mice with colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(5): 670-675.
[8]	Jiyue ZHU,Bo ZHANG,Yaru LI,Liuye. HUANG. The predictive value of the systemic inflammation response index for non⁃curative resection after endoscopic submucosal dissection for early colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(5): 716-723.
[9]	Yi WEI,Chunhui RAO,Huize LIU,Wen. CHEN. Predictive value of multimodal nomogram on the risk of metastasis and recurrence in patients with stage Ⅱ colorectal cancer without adjuvant treatment [J]. The Journal of Practical Medicine, 2025, 41(23): 3723-3729.
[10]	Mei HUA,Xiaolu ZHAI,Chong TANG,Ying CHEN,Dian YIN. Expression of serum microRNA⁃497 in patients with colorectal cancer and its diagnostic and prognostic values [J]. The Journal of Practical Medicine, 2025, 41(22): 3579-3584.
[11]	. Expert consensus on genetic testing for metastatic colorectal cancer patients based on tumor heterogeneity [J]. The Journal of Practical Medicine, 2025, 41(19): 2961-2966.
[12]	Tingting HU,Jing. ZHANG. The effect of Quadratus lumborum block combined with etomidate anesthesia on the quality of recovery and intestinal barrier function in elderly patients undergoing colorectal cancer surgery [J]. The Journal of Practical Medicine, 2025, 41(19): 2979-2984.
[13]	Cuicui WANG,Wantong QIAO,Junying YAO,Qian LI,Weige GAO,Min FAN. Clinical application value of nutritional control status score combined with prognostic nutritional index in evaluating the risk of anemia in elderly colorectal cancer patients [J]. The Journal of Practical Medicine, 2025, 41(17): 2696-2704.
[14]	Mengying ZHANG,Yaokai MA,Yifan DU,Wei ZHANG,Bo ZHOU,Xiyi YANG. A Randomized controlled study on the efficacy of HAIC sequential DEB⁃TACE in the treatment of colorectal cancer liver metastasis [J]. The Journal of Practical Medicine, 2025, 41(17): 2721-2728.
[15]	Yi LU,Shilong DAI,Mingjun WANG,Jing ZHOU,Junying HAO,Chen ZHENG,Xinbo XU,Shan DING,Qingsong ZHANG. The relationship between the triglyceride⁃glucose index and its modified index and colorectal cancer： A prospective cohort study [J]. The Journal of Practical Medicine, 2025, 41(15): 2362-2371.